Copyright
©The Author(s) 2021.
World J Cardiol. Sep 26, 2021; 13(9): 456-463
Published online Sep 26, 2021. doi: 10.4330/wjc.v13.i9.456
Published online Sep 26, 2021. doi: 10.4330/wjc.v13.i9.456
Drug class | Common drugs | Usual drug dosage | Indication |
CCB | Amlodipine; Diltiazem; Nifedipine-ER | 10 mg qD; 240 mg qD; 30-120 mg qD | First line for CAVS[40-42] |
Long-acting nitrate | Isosorbide mononitrate | 60–240 mg qD (maintenance) | Symptomatic improvement in combination with first line therapy[2] |
Short-acting nitrate | Sublingual nitroglycerin | 0.3 mg | Acute attack[43] |
Statin | Lovastatin; Fluvastatin | 80 mg qD; 20-80 mg qD | All patients experiencing CAVS[15,44] |
ACE inhibitor/ARB | Candesartan; Losartan | 8-16 mg qD; 25–50 mg qD | All patients experiencing CAVS[45] |
BB | Bisoprolol; Nebivolol | 1.25–5 mg qD; 5–10 mg qD | DES-VSA[37,38] |
Rho kinase inhibitors | Fasudil | 240 mg qD | Refractory CAVS[46] |
Antioxidants | Vitamin E | 400 mg qD | Adjunct therapy[47] |
Magnesium | Magnesium Chloride | 20 mEq | Replenishing deficiency[5] |
Potassium channel activator | Nicorandil | 10–20 mg BID | If nitrates are ineffective[12] |
- Citation: Jewulski J, Khanal S, Dahal K. Coronary vasospasm: A narrative review. World J Cardiol 2021; 13(9): 456-463
- URL: https://www.wjgnet.com/1949-8462/full/v13/i9/456.htm
- DOI: https://dx.doi.org/10.4330/wjc.v13.i9.456